KIERAN MUDRYY

Kieran Mudryy stands as a pivotal Partner at 4BIO Capital, a distinguished venture capital firm dedicated to pioneering investments in advanced therapies. With a profound understanding of the life sciences landscape, Kieran is instrumental in driving the firm's mission to identify, fund, and cultivate companies that are developing transformative treatments for severe diseases.

At 4BIO Capital, Kieran's responsibilities encompass a broad spectrum of investment activities. He is deeply involved in deal sourcing, meticulously evaluating potential investment opportunities, and conducting rigorous due diligence to ensure strategic alignment and scientific validity. Furthermore, he plays a significant role in portfolio management, working closely with nascent biotech companies to guide their growth, strategic development, and market entry. His expertise helps translate cutting-edge scientific discoveries into viable commercial ventures with the potential to impact patient lives.

Kieran's investment focus is sharply honed on the most innovative segments of advanced therapies. This includes gene therapy, cell therapy, RNA therapeutics, oligonucleotide technologies, and microbiome-based interventions. He seeks out companies that are pushing the boundaries of medical science, particularly those addressing high unmet medical needs across various therapeutic areas. His work at 4BIO Capital exemplifies a commitment to fostering breakthroughs that can redefine healthcare paradigms.

Before joining 4BIO Capital, Kieran honed his investment acumen at Syncona Ltd, a prominent life sciences investment company, where he served as an Investment Manager. In this role, he gained invaluable experience in company building and financing within the biotech sector, contributing to the creation and scaling of several innovative enterprises. His earlier career saw him in healthcare investment banking roles at Credit Suisse and Jefferies, where he developed a robust foundation in financial analysis, transaction execution, and strategic advisory for pharmaceutical and biotechnology companies. This diverse background provides him with a unique blend of scientific understanding, financial expertise, and strategic insight.

Kieran's academic background further underpins his capabilities. He holds an MPhil in Bioscience Enterprise from the University of Cambridge, complementing his BSc in Biochemistry from the University of Bristol. This strong scientific foundation, combined with his business acumen, allows him to critically assess complex scientific propositions and identify their commercial potential. While specific individual investments are often a collaborative effort, Kieran's involvement at 4BIO Capital means he contributes to the growth of companies like Ray Therapeutics, focused on gene therapy for retinal diseases, and Code Biotherapeutics, developing non-viral gene therapy platforms, among others in the firm's innovative portfolio. His dedication ensures that 4BIO Capital remains at the forefront of advanced therapy investment, driving the next generation of medical innovation.